Toward rational therapy for mantle cell lymphoma
Blood · 2023
DOI: 10.1182/blood.2023021817 ↗Kurz gefasst
Editorial in der Zeitschrift Blood, 2023. Verfasst von Mark A Murakami. Beteiligte Einrichtung: Dana-Farber Cancer Institute. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Lymphoma, B-Cell. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
decreased in vivo repopulating capacity compared with HSCs cultured with young stromal cells.Treatment of mice bearing Fancd2-or Atm-deficient stromal cells, as well as aged mice, with anti-AREG antibody partially corrected the HSC repopulating capacity defect in these animals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute.
ORCID-Profile: Mark A Murakami
Zitieren
APA
Murakami, M. A. (2023). Toward rational therapy for mantle cell lymphoma. Blood. https://doi.org/10.1182/blood.2023021817
Vancouver
Murakami MA. Toward rational therapy for mantle cell lymphoma. Blood. 2023. doi:10.1182/blood.2023021817
BibTeX
@article{Murakami2023,
author = {Murakami, Mark A},
title = {Toward rational therapy for mantle cell lymphoma},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2023021817}
}
EUVIMED